2022
Immunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunization, SecondaryProspective StudiesConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDoses
2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunogenicity, VaccineProspective StudiesSARS-CoV-2ConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply